94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Mariana Reste1†Kristi Ajazi2†Ayca Sayi-Yazgan3,4Radmila Jankovic5Biljana Bufan6Sven Brandau7Espen S. Bækkevold8Florent Petitprez9Malin Lindstedt2*Gosse J. Adema10*
Catarina R. Almeida1*- 1Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal
- 2Department of Immunotechnology, Lund University, Lund, Sweden
- 3Department of Molecular Biology and Genetics, Faculty of Science and Letters, Istanbul Technical University, Istanbul, Türkiye
- 4Department of Life Sciences, Centre for Inflammation Research and Translational Medicine, College of Health and Life Sciences, Brunel University London, Uxbridge, United Kingdom
- 5Faculty of Medicine, Institute of Pathology, University of Belgrade, Belgrade, Serbia
- 6Department of Microbiology and Immunology, University of Belgrade - Faculty of Pharmacy, Belgrade, Serbia
- 7Experimental and Translational Research, Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
- 8Department of Pathology, Oslo University Hospital-Rikshospitalet, Oslo, Norway
- 9Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, United Kingdom
- 10Radiotherapy & OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands
A Corrigendum on
The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases
By Reste M, Ajazi K, Sayi-Yazgan A, Jankovic R, Bufan B, Brandau S, Bækkevold ES, Petitprez F, Lindstedt M, Adema GJ and Almeida CR (2024) Front. Immunol. 15:1439413. doi: 10.3389/fimmu.2024.1439413
In the published article, there was an error in the Funding statement. The section originally stated that “COST is supported by the EU Framework Program Horizon 2020”, while it should refer to “Horizon Europe”. The correct Funding statement appears below.
“The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was developed within the scope of projects with references UIDB/04501/2020 and https://doi.org/10.54499/UIDB/04501/2020, UIDP/04501/2020 and https://doi.org/10.54499/UIDP/04501/2020, 2022.03217.PTDC and DOI 10.54499/2022.03217.PTDC, financially supported by national funds (OE), through FCT - Fundação para a Ciência e Tecnologia, I.P./MCTES. This work was also supported by the World Scleroderma Foundation and Edit Busch Stiftung (MAPFib). This work has been supported by Ministry of Science, Technological Development and Innovation, Republic of Serbia through Grant Agreement with University of Belgrade, Faculty of Medicine No: 451-03-66/2024-03/200110. This work was funded by the Ministry of Science, Technological Development and Innovation, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-47/2023-01/200161. This work was supported by the Wellcome Trust (225021/Z/22/Z). This work was supported by the Swedish Cancer Society (22 2221.Pj.01.H) and Mrs. Berta Kamprad’s Cancer Foundation (FBKS-2022-8-368). This work was supported by the Scientific and Technological Research Council of Turkey- TUBITAK (119S447 and 22AG077). This work was also supported by European Cooperation in Science and Technology (COST) Action CA20117 Mye-InfoBank (www.mye-infobank.eu); COST is supported by the EU Framework Program Horizon Europe.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: tertiary lymphoid structures (TLS), tertiary lymphoid organs (TLO), dendritic cells (DC), anti-tumor immunity, autoimmunity
Citation: Reste M, Ajazi K, Sayi-Yazgan A, Jankovic R, Bufan B, Brandau S, Bækkevold ES, Petitprez F, Lindstedt M, Adema GJ and Almeida CR (2025) Corrigendum: The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases. Front. Immunol. 16:1538818. doi: 10.3389/fimmu.2025.1538818
Received: 03 December 2024; Accepted: 28 January 2025;
Published: 07 February 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Reste, Ajazi, Sayi-Yazgan, Jankovic, Bufan, Brandau, Bækkevold, Petitprez, Lindstedt, Adema and Almeida. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Malin Lindstedt, bWFsaW4ubGluZHN0ZWR0QGltbXVuLmx0aC5zZQ==; Gosse J. Adema, R29zc2UuQWRlbWFAcmFkYm91ZHVtYy5ubA==; Catarina R. Almeida, Y3JhQHVhLnB0
†These authors have contributed equally to this work and share first authorship